Why the Alcidion (ASX:ALC) share price is falling again today

The Alcidion Group Ltd (ASX: ALC) share price has continued its negative run this week and is again backtracking today. We take a closer look into why.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Alcidion Group Ltd (ASX: ALC) share price has continued its negative run this week and is again backtracking today. This comes despite the company announcing the completion of its Share Purchase Plan (SSP).

In mid-afternoon trade, the healthcare technology company's shares are down 1.35% to 37 cents.

white arrow dropping down representing the 10 most shorted shares on the ASX

Image source: Getty Images

Why is the Alcidion share price on a downhill trend?

A possible catalyst for the fall of Alcidion shares is that investors are bracing for an impending share dilution.

According to Alcidion's release, the company advised it has successfully completed its SSP following 'very strong support' from shareholders. Over 1,900 applications were received, totalling roughly $30 million. This represents a huge level of investment when compared to the company's target of $2.5 million.

As a result, the board has decided to increase its SPP offer size to $3 million and scale back applications.

With the revised amount, roughly 9.37 million ordinary shares will be issued at a price of 32 cents apiece.

Most applicants will be allotted the minimum basic entitlement of 3,125 SPP shares (worth $1,000). Any remaining SSP shares will be issued on a pro-rata basis on the size of the applicant's shareholding at the record date.

Investors who sold their parcel of shares between the record date and SSP closing date or held less than 1,471 shares will not receive any shares.

Alcidion expects the new shares to be issued and available for trading from next Tuesday.

The capital raising follows the successful institutional placement that was announced on 15 April 2021.

Together, the combined funds for both the placement and SSP will give Alcidion a cash injection of $18.4 million.

Comments from the CEO

Alcidion CEO, Kate Quirke commented on the result of the SSP:

The Company would like to thank all shareholders who participated in the Share Purchase Plan and the Placement for their continued support. We acknowledge that shareholders who subscribed may be disappointed by the scale back. Ultimately, balancing the strong SPP participation with the foreseeable capital needs of the business is in the best interests of all shareholders.

Alcidion share price review

Although Alcidion shares might be modestly lower today, for this week alone, shareholders have recorded a loss of almost 10%. However, when looking at the bigger picture, in year-to-date performance, the Alcidion share price has doubled.

The company has a market capitalisation of approximately $384 million, with more than 1 billion shares on issue.

Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Alcidion Group Ltd. The Motley Fool Australia has recommended Alcidion Group Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

ASX 300 healthcare stock outperforming today on 'strategic' leadership news

The ASX healthcare stock announced the outcome of its CEO recruitment drive this morning.

Read more »

Cropped shot of a young female scientist working on her computer in the laboratory.
Healthcare Shares

Could Telix shares be a millionaire-maker stock?

Telix looks a compelling growth story, with brokers eyeing more than 150% upside.

Read more »

A child covering his eyes hiding from a toy bear.
Healthcare Shares

Down 20% in 2026, is now the time to buy CSL shares?

CSL shares hit a new multi-year low as the 2026 decline deepens.

Read more »

Scientists in white coats look disappointed.
Healthcare Shares

Down 87% since Thursday, why is this ASX 300 healthcare stock sliding again today?

The ASX healthcare share has plunged more than 87% in five trading days.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Which ASX biotech's shares have jumped more than 10% on positive clinical trial news?

A potential cancer treatment is progressing.

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

3 ASX healthcare stocks tipped to soar over 100% higher this year

These ASX shares are on my radar this week.

Read more »

Scientists working in the laboratory and examining results.
Opinions

3 reasons to buy CSL shares today

The ASX biotech company has great growth potential this year.

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »